News

Indevus originally licensed worldwide rights to aminocandin from Sanofi-Aventis in 2003. Aminocandin is a member of the echinocandin class of anti-fungal compounds for the treatment of a broad

The funding is part of the organizations LEAD program to drive and accelerate the development of innovative and effective multiple myeloma treatments. The Multiple Myeloma Research Foundation (MMRF)

The positive results are from a phase II study where a statistically significant proportion of patients on active treatment obtained a 20% improvement of the American College of

Nalmefene did not demonstrate a statistically significant difference compared to placebo on the primary endpoint, a test of obsessive compulsive behavior, at the doses 20 mg and 40

The phase III European and Canadian psoriasis trial will be performed at thirty-six clinical centers in Canada, Germany, and Poland involving a total of 500 patients with moderate

The trial is designed to identify the optimum dose and to yield safety and tolerability data for escalating doses of a Dynavax TLR9 agonist administered with irinotecan and

In the study, type 2 diabetes patients not currently treated with anti-diabetic medications and receiving Acomplia significantly lowered their HbA1c blood sugar levels by 0.8% from a baseline

This phase II trial will compare two doses of epinastine nasal spray to placebo. The trial will be conducted during the mountain cedar pollen season, which typically begins

Isis said the unnamed compound takes advantage of its expertise in nucleic acid therapeutics. The company's research is focused exclusively on the therapeutic target, RNA and focuses on